Posted on:

What is the brand name for levodopa and carbidopa combination?

In the pharmaceutical industry, the combination of Levodopa and Carbidopa is the “Gold Standard” for the management of Parkinson’s disease. As a pharmacist and manufacturer, I classify this as a dopamine precursor and decarboxylase inhibitor combination.

While Sinemet is the global innovator brand, there are several key regional and generic brands that are highly relevant for your B2B marketplace and export operations.

Primary Brand Names

RegionBrand NameManufacturer (Innovator/Major)
Global / USASinemetMerck (Innovator) / Organon
IndiaSyndopaSun Pharmaceutical Industries
IndiaLCDIntas Pharmaceuticals
IndiaTidometTorrent Pharmaceuticals
Global (Extended Release)RytaryAmneal Pharmaceuticals
Global (Intestinal Gel)DuopaAbbVie

Mechanism: The “Trojan Horse” Strategy

The reason these two are combined is a classic example of pharmacokinetic synergy. Levodopa alone is highly inefficient because it is destroyed before it reaches the brain.

Levodopa (The Precursor): Levodopa can cross the Blood-Brain Barrier (BBB). Once inside the brain, it is converted into Dopamine, restoring the levels needed for smooth muscle movement.

Carbidopa (The Protector): Carbidopa cannot cross the BBB. Its job is to stay in the bloodstream and block the enzyme DOPA Decarboxylase. This prevents Levodopa from being converted to dopamine in the body (periphery).

The Result: By protecting Levodopa in the bloodstream, Carbidopa allows more of it to reach the brain. This also significantly reduces side effects like severe nausea and vomiting caused by dopamine in the blood.

The Manufacturer’s Perspective: Technical & Export

From a production and B2B standpoint at your WHO-GMP facility in Mumbai, this combination is a high-precision CNS (Central Nervous System) product:

  • The 4:1 and 10:1 Ratios: On your marketplace, you should highlight that you offer standard ratios like 100/10 mg, 100/25 mg, and 250/25 mg. Explaining these ratios to B2B buyers shows your technical manufacturing expertise.

  • Extended Release (CR) Formulations: Promoting a Controlled Release (CR) version is a major USP. It reduces “wearing-off” effects for patients, making your product more attractive to international hospital networks.

  • Stability & Moisture Sensitivity: Levodopa is sensitive to light and moisture. At our facility, we utilize Alu-Alu blister packaging to ensure a 36-month shelf life, which is essential for export to tropical Zone IVb regions.

  • Dossier Readiness: Since Parkinson’s requires lifelong treatment, we maintain full CTD/eCTD Dossiers to support your firm in bidding for long-term government health contracts and insurance tenders.

Carbidopa and Levodopa Tablets